The History and Development of HER2 Inhibitors

HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mai...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Xiaohui, Gong, Chen, Zhang, Yinan, Xiong, Huihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610116/
https://www.ncbi.nlm.nih.gov/pubmed/37895921
http://dx.doi.org/10.3390/ph16101450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610116/
https://www.ncbi.nlm.nih.gov/pubmed/37895921
http://dx.doi.org/10.3390/ph16101450

Ejemplares similares